Results 81 to 90 of about 2,071 (176)

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)

Dermatology Practical & Conceptual
Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment.
Diego Orsini, Piergiorgio Malagoli, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Valentina Dini, Maria Esposito, Maria C. Fargnoli, Francesca M. Gaiani, Luigi Gargiulo, Paolo Gisondi, Alessandro Giunta, Luciano Ibba, Claudia Lasagni, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Alessandra Narcisi, Annamaria Offidani, Giovanni Paolino, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Chiara Assorgi, Antonio Costanzo   +44 more
doaj   +1 more source

Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Rheumatology and Therapy
This Summary of Research summarises results from the BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581) studies and their open-label extension, BE VITAL (NCT04009499).
Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates   +13 more
doaj   +1 more source

Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies. [PDF]

OBJECTIVE: To assess the longer-term effect of bimekizumab up to 1 year on patient-reported symptoms, health-related quality of life (HRQOL), and work productivity in patients with active PsA who were biologic disease-modifying antirheumatic drug (bDMARD)
Gladman, Dafna D, Bajracharya, Rajan, Lambert, Jérémy, Gladman, Dafna, Mease, Philip J, Gossec, Laure, Gottlieb, Alice B, Gottlieb, Alice, Husni, M Elaine, Tillett, William, Husni, M. Elaine, Coarse, Jason, Ink, Barbara, Lyris, Nikos, Mease, Philip   +14 more
core   +1 more source

An evaluation of bimekizumab for the treatment of hidradenitis suppurativa

Expert Opinion on Biological Therapy
Until recently, the biological treatment options for hidradenitis suppurativa (HS) were largely restricted to adalimumab and secukinumab. In 2024, bimekizumab, an IL-17A and IL-17F antibody was introduced to the clinical practice.Bimekizumab offers a new therapeutic approach for managing HS. It was approved by the U.S Food and Drug Administration (FDA)
Tomasz, Skrzypczak, Anna, Skrzypczak, Łukasz, Matusiak, Jacek C, Szepietowski   +3 more
openaire   +2 more sources

Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials

Dermatology and Therapy
Introduction Psoriasis in high-impact areas, including the scalp, nails, palms, and soles, can disproportionately impair patient quality of life. Here, we evaluate the 2-year efficacy of bimekizumab treatment in patients with moderate to severe plaque ...
Joseph F. Merola, Alice B. Gottlieb, Andreas Pinter, Boni Elewski, Melinda Gooderham, Richard B. Warren, Stefano Piaserico, Krista Wixted, Nancy Cross, Nicola Tilt, Susanne Wiegratz, Ulrich Mrowietz   +11 more
doaj   +1 more source

Rapid and sustained improvement of psoriasis with Bimekizumab: A real‐world case series

JEADV Clinical Practice
This retrospective case series examines the efficacy and safety of Bimekizumab in 22 patients with moderate to severe plaque psoriasis in a real‐world clinical setting.
Sergio Santos‐Alarcón, Francisco Javier Mataix‐Diaz, Constantin Luca Schneller‐Pavelescu Apetrei, Isabel Belinchón‐Romero   +3 more
doaj   +1 more source

Treatment of Pyoderma Gangrenosum With Bimekizumab

JEADV Clinical Practice
Pyoderma gangrenosum (PG) is an inflammatory neutrophilic dermatosis with no FDA‐approved treatments. Current therapies, including corticosteroids and immunomodulators, often show limited efficacy and nonspecific, conferring to higher risk of adverse ...
Kareena S. Garg, Adeel Ahmad, Leonardo Tjahjono   +2 more
doaj   +1 more source

Real-world evaluation of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: A nationwide retrospective cohort study on behalf of the HS-SIDeMaST task force - Supplementary Materials

Supplementary material Supplementary Material 1: Statistical methods Supplementary Material 2 - Table 1: Data stratified according to bimekizumab dose regimen Supplementary Material 3 - Table 2: Data stratified according to bimekizumab bio-naïve ...
Avallone, Gianluca
core   +1 more source

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study

Bimekizumab is a novel interleukin (IL)-17A/IL-17F inhibitor approved for the treatment of moderate-to-severe plaque psoriasis in adult patients. While its efficacy and safety have been demonstrated in several clinical trials, real-world data remains ...
Sood, S (via Mendeley Data)
core   +1 more source

Psoriasis Treatment Success With Bimekizumab: Two Hard-to-Treat Cases. [PDF]

Cureus
Ameen A.
europepmc   +1 more source